ArticleArrhythmia & electrophysiology review2016
Antiarrhythmic Drug Therapy to Avoid Implantable Cardioverter Defibrillator Shocks.
Article in Arrhythmia & electrophysiology review, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Changing Antiarrhythmic Drug Regimen in Patients with Amiodarone and Ablation Refractory Ventricular Tachyarrhythmias Is Associated with Increased Implantable Cardioverter Defibrillator Shocks-A Retrospective Analysis from a Large Tertiary Center.Journal of clinical medicine · 2025Article
- Feasibility of volumetric-modulated arc therapy gating for cardiac radioablation using real-time ECG signal acquisition and a dynamic phantom.Medical physics · 2025Article
- Incidence, Risk Factors and Predictors of Phantom Shocks in Patients with Implantable Cardioverter Defibrillators: State-of-the-art Review.Arrhythmia & electrophysiology review · 2024Review
- Overview of Cardiac Arrhythmias and Treatment Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Evaluation of the feasibility of cardiac gating for SBRT of ventricular tachycardia based on real-time ECG signal acquisition.Journal of applied clinical medical physics · 2023Article
- SBRT of ventricular tachycardia using 4pi optimized trajectories.Journal of applied clinical medical physics · 2021Article
- Recommendations for driving after implantable cardioverter defibrillator implantation and the use of a wearable cardioverter defibrillator : Different viewpoints around the world.Wiener klinische Wochenschrift · 2020Review
- Strategies to Reduce Recurrent Shocks Due to Ventricular Arrhythmias in Patients with an Implanted Cardioverter-Defibrillator.Arrhythmia & electrophysiology review · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Implantable cardioverter defibrillators (ICDs) are effective in the prevention of arrhythmic sudden cardiac death. Many patients receiving an ICD are affected by heart failure and are at risk of ventricular arrhythmias, which may lead to appropriate shocks. On the other hand, in this population the incidence of atrial fibrillation, giving rise to inappropriate ICD shocks, is high. Accordingly, ICD discharges occur frequently and many patients with an ICD will need concomitant antiarrhythmic drug therapy to avoid or reduce the frequency of shocks. Therapeutic agents such as β-blockers, class I or class III antiarrhythmic drugs effectively suppress arrhythmias, but may have side-effects. Some drugs could eventually influence the function of ICDs by altering defibrillation or pacing threshold. Few prospective randomised trials are available, but current data suggest that amiodarone is most effective for prevention of appropriate or inappropriate ICD shocks. This review article summarises current knowledge regarding the antiarrhythmic management of patients with ICDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.